Compares JNJ-79635322 with teclistamab in relapsed or refractory multiple myeloma
Compares JNJ-79635322 with teclistamab in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Albany, Atlanta, Baltimore, Beverly Hills, Birmingham, Boston, Canton, Chicago, Cincinnati, Dallas, Dayton, Denver, Detroit, Durham, East Brunswick, Eugene, Farmington, Greenville, Indianapolis, Iowa City, Irvine, Jacksonville, Los Angeles, Louisville, Lubbock, Mineola, Minneapolis, Nashville, New York, Omaha, Orange, Pembroke Pines, Phoenix, Rochester, Salt Lake City, Santa Fe, Shirley, Shreveport, Springdale, Tacoma, and Waukee, United StatesSee the 41 sites
- Phase
- Phase 3
Where in United States
- New York Oncology HematologyAlbany, United StatesTaking people
- Emory UniversityAtlanta, United StatesTaking people
- Johns Hopkins HospitalBaltimore, United StatesTaking people
- Beverly Hills Cancer Center Clinical Research Advisors LLCBeverly Hills, United StatesTaking people
- Alabama OncologyBirmingham, United StatesTaking people
- Tufts Medical CenterBoston, United StatesTaking people
- Gabrail Cancer CenterCanton, United StatesTaking people
- Rush University System for HealthChicago, United StatesTaking people
- The Christ HospitalCincinnati, United StatesTaking people
- Baylor University Medical CenterDallas, United StatesTaking people
- Dayton Physicians Network UrologyDayton, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- Karmanos Cancer InstituteDetroit, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- Astera Cancer CareEast Brunswick, United StatesTaking people
- Willamette Valley Cancer Institute and Research CenterEugene, United StatesTaking people
- University of Connecticut Health CenterFarmington, United StatesTaking people
- Bon Secours Saint Francis Cancer CenterGreenville, United StatesTaking people
- Franciscan HealthIndianapolis, United StatesTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesTaking people
- UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesTaking people
- Mayo Clinic- JacksonvilleJacksonville, United StatesTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesTaking people
- Norton Cancer InstituteLouisville, United StatesTaking people
- Joe Arrington Cancer Research Treatment CenterLubbock, United StatesTaking people
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, United StatesTaking people
- University of Minnesota Medical CenterMinneapolis, United StatesTaking people
- Tennessee Oncology, PLLCNashville, United StatesTaking people
- NYU Langone Health ManhattanNew York, United StatesTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesTaking people
- University of California Irvine Medical CenterOrange, United StatesTaking people
- Memorial Cancer InstitutePembroke Pines, United StatesTaking people
- Mayo Clinic 1Phoenix, United StatesTaking people
- Mayo ClinicRochester, United StatesTaking people
- Utah Cancer SpecialistsSalt Lake City, United StatesTaking people
- CHRISTUS St. Vincent Regional Cancer CenterSanta Fe, United StatesTaking people
- New York Cancer and Blood SpecialistsShirley, United StatesTaking people
- LSU Health Feist Weiller Cancer CenterShreveport, United StatesTaking people
- Highlands Oncology GroupSpringdale, United StatesTaking people
- Northwest Medical Specialties PLLCTacoma, United StatesTaking people
- Mission Cancer Blood University of Iowa Health CareWaukee, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07518186
- Record updated
- 25 September 2026
- Original description
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.Read full original descriptionShow less
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Inclusion: Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory; Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide; Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication; Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment.
Exclusion: Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study; Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required; Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients; Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM.